-
-
-
-
-
-
-
FDA grants priority review to Astellas-Pfizer cancer drug application
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
-
-
-
-
-
-
-
Pfizer (PFE) and Genmab (GMAB) Reports TIVDAK sBLA Accepted for Priority Review by FDA
-
-
-
-
-
-
-
Pfizer (PFE) Reports FDA Priority Review Granted for XTANDI
-
-
-
-
-
-
-
Pfizer (PFE) Reports AdCom Vote in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
-
-
-
-
-
-
-
Pfizer (PFE) Announces Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
-
15,606 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

